Earnings ·
Allogene Therapeutics reports Q3 net loss of $50.4M and ends quarter with $388.9M in cash
ALLOAllogene Therapeutics, Inc.
Allogene Therapeutics reported a third-quarter 2026 net loss of $50.4 million, or $0.15 per share, driven by research and development expenses of $41.9 million and general and administrative costs of $12.9 million. The company ended the quarter with $388.9 million in cash, cash equivalents, and investments, projecting its cash runway into 2029. Management provided updates on clinical programs, including enrollment momentum for the pivotal ALPHA3 trial in large B-cell lymphoma and upcoming data presentations for ALLO-329 in autoimmune disease. Allogene Therapeutics is a clinical-stage biotechnology company pioneering the development of allogeneic CAR T products for cancer and autoimmune disease.